Author

Joseph Mitchell McIntosh

The University of Texas MD Anderson Cancer Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1 Research Focus:transcription & RNA processing· 1

Frequent Co-Authors

Changying JiangiD· 1 shared Haiying CheniD· 1 shared Hong KimiD· 1 shared Jia ZhouiD· 1 shared Lei NieiD· 1 shared Michael L. WangiD· 1 shared Qingsong CaiiD· 1 shared Tianci ZhangiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Changying JiangORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

YX0798 Is a Highly Potent, Selective, and Orally Effective CDK9 Inhibitor for Treating Aggressive Lymphoma

Changying Jiang, Yu Xue, Hong Kim, Qingsong Cai, Tianci Zhang, Lei Nie, Joseph Mitchell McIntosh, Yang Liu, Haiying Chen, Jia Zhou, Michael L. Wang

This paper identifies YX0798 as a potent, selective, and orally effective CDK9 inhibitor that overcomes therapeutic resistance in lymphoma by inducing transcription reprogramming and cell death.

Blood Advances · Jul 21, 2025Peer-reviewedCancer Biology